DV
Dividend Vision

PBLS — Parabilis Medicines, Inc. Common Stock

Parabilis Medicines, Inc. Common Stock (PBLS)

Total return is 17.3% over the past 0.2 years, 10.0 points ahead of SPY at 7.3%.

Parabilis Medicines is a clinical-stage biopharmaceutical company developing helical peptide therapeutics designed to target proteins traditionally considered undruggable, including functional inhibitors of protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals. The company does not currently distribute dividends. This security appeals primarily to investors with high risk tolerance seeking exposure to early-stage drug development, as Parabilis remains pre-revenue and dependent on the success of its lead clinical program and pipeline advancement.

PBLS key facts

Asset type
Stock
Asset class
Equity
Inception date
06/10/2026
Last close
$37.07
Market cap
$3,452,268,800
Average volume
290900.0
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.77